Acute and Subacute Effects of EV Iron Sucrose on Endothelial Functions in Hemodialysis Patients

REFERENCES

• Eshbach JW, Egrie JC, Downing MR, Brown JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant erythropoietin. N Engl J Med. 1987;316:73–78.
   PubMed Web of Science ®Google Scholar
• Agarwal R. Iron oxidative stress, and clinical outcomes. Pediatr Nephrol. 2008;23:1195–1199.
   PubMedGoogle Scholar
• Anonymous. National Kidney Foundation. K/DOQI Clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis. 2001;37:182–238.
   Google Scholar
• K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(Suppl 3):51.
   PubMedGoogle Scholar
• Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol. 2006;1:19–23.
   PubMedGoogle Scholar
• Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. J Am Med Assoc. 1980;243:1726–1731.
   PubMed Web of Science ®Google Scholar
• Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am J Kidney Dis. 1999;33:464–470.
   PubMed Web of Science ®Google Scholar
• Michael B, Coyne DW, Fishbane S, . Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int. 2002;61:1830–1839.
   PubMed Web of Science ®Google Scholar
• Charytan C, Levin N, Al Saloum M, Hafeez T, Gagnon S,Van Wyck DB. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis. 2001;37:300–307.
   PubMedGoogle Scholar
• Shah SV, Alam MG. Role of iron in atherosclerosis. Am J Kidney Dis. 2003;41:80–83.
   PubMed Web of Science ®Google Scholar
• Borawski J, Gozdzikiewicz J, Abramowicz P, Naumnik B, Mysliwiec M. Endothelial injury markers with high dose intravenous iron therapy in renal failure. Clin Appl Thromb Hemost. 2004;10(4):403–406.
   PubMedGoogle Scholar
• Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: A comparatıve toxicologic analysis and mechanism of cell injury. Am J Kidney Dis. 2002;40:90–103.
   PubMed Web of Science ®Google Scholar
• Fernandez NG, Echeverrıa A, Ibarrola AS, Paramo JA, Canella IC. Randomized clinical trial on acute effects of i.v. iron sucrose during hemodialysis. Nephrology. 2010;15:178–183.
   PubMedGoogle Scholar
• Sağlam F, Cavdar C, Uysal S, Cavdar Z, Camsarı T. Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patient. Ren Fail. 2007;29(7):849–854.
   PubMed Web of Science ®Google Scholar
• Drüeke T, Witko-Sarsat V, Massy Z, . İron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002;106:2212–2217.
   PubMed Web of Science ®Google Scholar
• Rooyakers TM, Stroes ES, Kooistra MP, . Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest. 2002;32:9–16.
   Web of Science ®Google Scholar
• Balanos L, Juanatey CG, Testa A, Ranero R. Intravenous iron sucrose dose not impaır sonografic brachial vasodilatation in peritoneal dialysis patients. Adv Perit Dial. 2008;24:90–95.
   PubMedGoogle Scholar
• Corretti MC, Anderson TJ, Benjamin EJ, . Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol. 2002;39:257–265.
   PubMed Web of Science ®Google Scholar
• Mimic-Oka J, Savic-Radojevic A, Pljesa-Ercegovac M, Opacic M, Simic T. Evaluation of oxidative stress after repeated intravenous iron supplementation. Ren Fail. 2005;27:345–351.
   PubMed Web of Science ®Google Scholar
• Bolton CH, Downs LG, Victory JGG, . Endothelial dysfunction in chronic renal failure: Roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2001;16:1189–1197.
   PubMed Web of Science ®Google Scholar
• Ghiadoni L, Cupisti A, Huang Y, . Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol. 2004;17:512–519.
   PubMedGoogle Scholar
• Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in hemodialysis patients receiving ıntravenous iron therapy. Nephrol Dial Transplant. 1999;14:2680–2687.
   PubMed Web of Science ®Google Scholar
• Cavdar C, Temiz A, Yenicerioğlu Y, . The effects of ıntravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patient. Scand J Urol Nephrol. 2003;37:77–82.
   PubMed Web of Science ®Google Scholar
• Ludat K, Sommerburg O, Grune T, Siems WG, Hampl H. Oxidation parameters in complete correction of renal anemia. Clin Nephrol. 2000;53:530–535.
   Google Scholar
• Mimic-Oca J, Simic T, Djukanovic LJ. Epoetin treatment improves red blood cell and plasma antioxidant capacity in hemodialysis patient. Ren Fail. 2002;24:77–87.
   PubMedGoogle Scholar
• Schaller G, Scheiber-Mojdehkar B, Wolzt M. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. Kidney Int. 2005;68:2814–2822.
   PubMed Web of Science ®Google Scholar